Hypertension
Conditions
Keywords
MRI, Hypertension
Brief summary
Investigators propose here to study the brain consequences of hypertension in patients without cognitive complaints and neurological signs. The evaluation of brain suffering requires considering various possible brain damage. The team developed a multimodal MRI approach capable of detecting and quantifying numerous indices (e.g. morphometric, microstructural) to evaluate possible brain suffering. This project aims to identify individually signs of cerebral suffering in hypertensive patients compared to a population of normotensive volunteers, using advanced multiparametric MRI methods.
Detailed description
Hypertension is a risk factor for many brain pathologies, such as ischemic and hemorrhagic neurodegenerative diseases or stroke. The literature seems to agree on the relationship between hypertension and brain damage, and on the benefit of the management of hypertension to prevent certain neurological pathologies. However, to our knowledge, no single study has shown signs of subclinical brain damage in patients with hypertension. At present, no brain MRI is recommended in these patients. In the present study, hypertensive and normotensive patients will undergo a neurological exam, a neuropsychological exam, a biological exam and a MRI exam to individually identify signs of cerebral suffering.
Interventions
DIAGNOSTIC_TESTmultimodal magnetic resonance imaging
Brain MRI exam (without contrast injection)
DIAGNOSTIC_TESTblood test
Blood test to evaluate cardiovascular risk factors (cholesterol, triglycerides, LDL and HDL-CT, serum creatinine, fasting glucose, serum potassium), .
DIAGNOSTIC_TESTneuropsychological assessment
neuropsychological assessment
Sponsors
Institut National de la Santé Et de la Recherche Médicale, France
University Hospital, Toulouse
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Investigator)
Eligibility
Sex/Gender
ALL
Age
35 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Male and female 35 to 50 y.o.;for patients: diagnosed HTA within 5 years, treated or confirmed by Ambulatory Blood Pressure Measure; * For normotensive participants:Absence of HTA confirmed by Ambulatory Blood Pressure Measure
Exclusion criteria
* Known neurological history, stroke, symptomatic headache, long-term use of neuroleptic, tricyclic, MAOI, anti-serotonergic antidepressant medications, diabetes mellitus, treated dyslipidemia, body mass index greater than 30 kg / m, participants who smoked or smoked more than 10 packs-year, MRI contraindication ; * For HTA patients only: Renal artery dysplasia responsible for hypertension, clinical Cushing Syndrome.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Presence of a cerebral zone with a z-score > 1.96 | through study completion, an average of 1 year | the proportion of hypertensive patients who have at least one sign of cerebral suffering compared to the control group will be determined. For each MRI parameter, after coregistration, z score maps will be calculated for each hypertensive patient (individual vs normotensive group). The notion of cerebral suffering sign will be defined by the presence of a cerebral zone with a z-score greater than 1.96 (corresponding to a threshold of significance p \<.05). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| White matter hypersignals | through study completion, an average of 1 year | FAZEKAS score estimating T2 hypersignals of the white matter, |
| Microbleeds | through study completion, an average of 1 year | number and location of microbleeds, |
| Gaps | through study completion, an average of 1 year | number of gaps |
Other
| Measure | Time frame | Description |
|---|---|---|
| Correlation between MRI data and clinical scales | through study completion, an average of 1 year | MRI parameters will be correlated with clinical and neuropsychological using Spearman 'rank correlation. |
Countries
France
Contacts
Primary ContactJean Darcourt, MD
Backup ContactPatrice Péran, PHD
Outcome results
None listed